Researchers are developing a new drug to treat life-threatening lung damage and breathing problems in people with severe infections like pneumonia, those undergoing certain cancer treatments and premature infants with underdeveloped, injury prone lungs.
This microscopic image shows tissues from an adult mouse lung in which the FOXF1 gene has been deleted in endothelial cells for two weeks. The lungs undergo thickening of tiny air sacs called alveolar and develop congestion and severe inflammation. This leads to pulmonary hemorrhaging, fibrosis in the lungs and death. In laboratory tests, an experimental compound being developed by researchers at Cincinnati Children’s Hospital Medical Center stabilizes FOXF1 and allows the lungs to recover. Researchers report their findings April 19 in the journal Science Signaling.
Credit: Cincinnati Children’s